A single-center observational study on the efficacy of percutaneous coronary intervention for ischemic heart failure

Zongtao Wang, Lijun Jin, Wanxing Zhou, Da Lei, Hong Yan, Huimin Yu, Zhihuan Zeng, Guiping Zhu, Jianyi Zheng, Yining Dai, Haifang WangMedicine 2018 · DOI

TL;DR

This single-center observational study investigated whether percutaneous coronary intervention (PCI) offers additional benefits for patients with ischemic heart failure (HF) already receiving optimal medical treatment. The findings suggest that PCI may improve cardiac systolic function and survival rates within a 3-month follow-up period, particularly when complete revascularization is achieved.

What Problem Does This Paper Address?

Heart failure (HF) remains a significant global health challenge, with ischemic heart disease (IHD), specifically coronary artery disease (CAD), being a primary cause. While optimal medical treatment (including medications like beta-blockers, ACEIs/ARBs, and aldosterone receptor antagonists) is the cornerstone for managing HF and CAD, the role of revascularization strategies, such as coronary artery bypass grafting (CABG) and PCI, in improving clinical outcomes for patients with both CAD and HF is still being determined. Previous large-scale trials like the STICH trial have shown benefits for CABG, but the specific contribution of PCI, a less invasive approach, in this patient population, especially when added to optimal medical therapy, requires further investigation. This study aims to fill this gap by evaluating the efficacy of PCI in improving cardiac function and clinical outcomes in patients with CAD and HF who are already on guideline-recommended medical treatment.

Methods

This was a single-center, prospective cohort study. Patients with confirmed CAD and HF were enrolled and treated with optimal medical therapy. Based on clinical judgment and coronary angiography/CT angiography findings, some patients also underwent PCI. Patients were then categorized into two main groups: those receiving optimal medical treatment alone and those receiving PCI in addition to optimal medical treatment. The PCI group was further subdivided into those who achieved complete revascularization (CR) and those who achieved partial revascularization (PR), defined by residual stenosis.

Baseline assessments included physical examinations, biochemical tests, ECG, and echocardiography. Follow-up occurred at 3 months and involved clinical assessment, biochemical tests, ECG, and echocardiography. The primary outcome measured was the change in left ventricular ejection fraction (LVEF) as an indicator of cardiac systolic function. The secondary outcome was a composite of major adverse cardiovascular events (MACEs), including all-cause death, cardiovascular death, nonfatal myocardial infarction, severe HF, angina recurrence, and rehospitalization or revascularization. Statistical analyses employed t-tests, ANOVA, chi-square tests, Fisher's exact test, and Kaplan-Meier survival analysis with log-rank tests.

Datasets

Not discussed in the paper. The study involved a cohort of 69 patients recruited from the Department of Cardiology of Guangdong General Hospital.

Key Insights and Ideas

  • PCI as an Adjunct to Optimal Medical Therapy: The study suggests that PCI, when added to optimal medical treatment, can offer tangible benefits beyond medication alone for patients with CAD and HF. This is crucial as it explores a less invasive revascularization option in a complex patient group.
  • LVEF Improvement with PCI: A significant finding is the improvement in LVEF observed in the PCI group after 3 months, while the medical treatment-only group showed no significant change. This points to a potential mechanism by which PCI might improve cardiac function.
  • Survival Benefit with PCI: Patients undergoing PCI demonstrated better survival rates within the 3-month follow-up compared to those on medical therapy alone. This highlights the potential of PCI to impact more critical clinical endpoints.
  • Complete Revascularization (CR) Appears More Promising: While not statistically significant, there was a trend towards better survival in patients who achieved complete revascularization (CR) with PCI compared to partial revascularization (PR). This suggests that achieving a more comprehensive restoration of blood flow might be key to maximizing benefits.
  • Unclear Impact of CR on LVEF: Interestingly, despite the survival trend, the study found no significant difference in LVEF improvement between the CR and PR groups, raising questions about the direct link between CR and systolic function improvement in this specific context.

Key Results

  • LVEF Improvement: Patients in the PCI group showed a significant improvement in LVEF (P < .001) after 3 months, while the medical treatment group did not (P > .05). At 3 months, LVEF was significantly higher in the PCI group (48.1% ± 11.2%) compared to the medical group (38.5% ± 13.9%, P=.045).
  • MACEs: MACEs occurred in 50% of patients in the medical treatment group versus 19.3% in the PCI group, a difference that "almost reaching statistical significance" (P=.06).
  • Survival: Patients who received PCI experienced significantly better survival within 3 months (P=.02) compared to those receiving medical therapy only.
  • CR vs. PR Survival: Survival appeared to be better in patients who achieved CR with PCI compared to those with PR (P=.06), though this difference was also "almost statistically significant."

Limitations and Future Work

The authors acknowledge several limitations:

  • Pilot Observational Study: The study's observational nature and limited sample size (69 patients) mean results could be confounded by unmatched variables. A randomized controlled trial (RCT) is needed for confirmation.
  • Small Sample Size for MACEs: The relatively small number of patients limits the statistical power to detect significant differences in MACE components.
  • Subjectivity in PCI Decisions: Decisions regarding PCI were based on interventional cardiologists' judgments, which can be subjective. Myocardial viability assessment was not performed prior to PCI, which could have guided treatment decisions more effectively.
  • Lack of CABG Comparison: The study did not compare PCI directly with CABG, another revascularization strategy, which is important given CABG's established benefits in similar patient populations.
  • Subgroup Analysis Difficulty: The small sample size made it difficult to evaluate whether specific subgroups of patients benefited more from PCI.

Future work should focus on large-scale RCTs to confirm these findings. The authors also suggest that future research should incorporate myocardial viability assessment to guide PCI in patients with IHF and compare PCI directly with CABG in this patient population. Identifying specific patient subgroups that benefit most from PCI is also a crucial area for future investigation.

Summary updated

Abstract

The effects of revascularization by percutaneous coronary intervention (PCI) on cardiac function and clinical outcomes in patients with confirmed coronary artery disease (CAD) and heart failure (HF), on the basis of the optimal medical treatment recommended by current guidelines, remain to be determined.A cohort study was performed to evaluate the efficacy of PCI on the basis of optimal medical treatment in patients with CAD and HF. Patients who received PCI were subsequently grouped according to partial and complete revascularization (CR) depending on the PCI outcome. The primary outcome was defined as a composite outcome of major adverse cardiovascular events (MACEs). Changes in left ventricular ejection fraction (LVEF) also were compared.A total of 69 patients (12 who received medical treatment and 57 who received PCI) were included. Patients in the PCI group showed significantly improved LVEF (P < .001), but patients in the medical treatment group did not (P > .05) after 3 months of follow-up. MACEs occurred in 50% patients in the medical treatment group and 19.3% patients of the PCI group, with this difference almost reaching statistical significance (P = .06). Compared with patients who received medical therapy only, patients who received PCI experienced better survival (P = .02). Moreover, survival seemed to be better in patients who achieved CR with PCI of the coronary arteries than in those who had partial revascularization of the coronary arteries (P = .06).PCI may be effective for improving survival in patients with CAD and HF.
BibTeX
@inproceedings{wang2018single,
  author = {Zongtao Wang and Lijun Jin and Wanxing Zhou and Da Lei and Hong Yan and Huimin Yu and Zhihuan Zeng and Guiping Zhu and Jianyi Zheng and Yining Dai and Haifang Wang},
  title = {{A single-center observational study on the efficacy of percutaneous coronary intervention for ischemic heart failure}},
  booktitle = {Medicine},
  year = {2018},
  doi = {10.1097/md.0000000000010238},
}
Figure